Canagliflozin Reduces Cardiorenal Biomarkers in T2D
WEDNESDAY, Aug. 23, 2023 -- For people with type 2 diabetes and albuminuria, canagliflozin reduces the longitudinal trajectory of increase in cardiorenal biomarkers, according to a study published online Aug. 22 in Circulation.
James L. Januzzi,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | Pharmaceuticals | Study